EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)

Aim. To study efficacy and safey of sinus rhythm restoration with amiodarone and propafenone in outpatients with recurrent atrial fibrillation (AF), and to estimate pharmacoeconomic efficiency of such cardioversion in comparison with hospital treatment.Material and methods. Patients (n=199; aged 59....

Full description

Bibliographic Details
Main Authors: T. A. Istomina, E. V. Serdechnaya, L. A. Kulminskaya, B. A. Tatarskiy, E. V. Kazakevich, V. L. Lipskiy, S. I. Martyushov
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/910
id doaj-6c641c084bcb4eb4b5f19f7ebe096835
record_format Article
spelling doaj-6c641c084bcb4eb4b5f19f7ebe0968352021-09-03T13:15:21ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-01-016677978810.20996/1819-6446-2010-6-6-779-788909EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)T. A. Istomina0E. V. Serdechnaya1L. A. Kulminskaya2B. A. Tatarskiy3E. V. Kazakevich4V. L. Lipskiy5S. I. Martyushov6N.A. Semashko Northern Medical Clinical Center, Federal Medical and Biological AgencyNorthern State Medical UniversityN.A. Semashko Northern Medical Clinical Center, Federal Medical and Biological AgencyV.A. Almazov Federal Centre of Heart, Blood and EndocrinologyN.A. Semashko Northern Medical Clinical Center, Federal Medical and Biological AgencyNorthern State Medical UniversityNorthern State Medical UniversityAim. To study efficacy and safey of sinus rhythm restoration with amiodarone and propafenone in outpatients with recurrent atrial fibrillation (AF), and to estimate pharmacoeconomic efficiency of such cardioversion in comparison with hospital treatment.Material and methods. Patients (n=199; aged 59.2±1.36) with paroxysmal (73.9%) or persistent (26.1%) AF were included into the multicenter prospective study. Follow-up period was 13.14 months (min 1 month, max 36 months). Patients with arrhythmia relapse <48 h received outpatient cardioversion with amiodarone or propafenone orally. Daily outpatient examination, including ECG and blood pressure monitoring every 30-60 min, was carried out to evaluate efficacy of cardioversion and hemodynamics. Phone contact with patients was available. Patients with unstable hemodynamics received cardioversion in hospital. Patients received propafenone in cumulative dose of 600 mg (150-300 mg every hour), and amiodarone 600-800 mg daily. The cost/effectiveness ratio (CER) was estimated. This ratio shows the cost of one unit of effect.Results. Outpatient cardioversion with amiodarone was started 24 h earlier (p=0.029) and with propafenone — 4.5 h earlier (p=0.002) than that in hospital. The average dose of amiodarone in ambulatory cardioversion was 1.3 times less (713.7±84,62 mg, p=0.345) than that in hospital cardioversion. Outpatient treatment with amiodarone restored sinus rhythm 8.7 h earlier, and with propafenone - 3.5 h earlier than the same treatments in hospital. Efficiency of hospital cardioversion with amiodarone was 70%, with propafenone - 80%, and efficiency of outpatient cardioversion — 96,1% and 98,4%, respectively. Outpatient treatment did not cause any severe side effects. Expenses for outpatient cardioversion made up 143 724.25 rubles, and for hospital cardioversion — 92 870.47 rubles. Average treatment costs for one patient in hospital was 6 times greater than for an outpatient. Outpatient cardioversion had the lowest CER (~1300 rubles%).Conclusion. Outpatient cardioversion with amiodarone or propafenone is not only effective and safe, but also economically feasible.https://www.rpcardio.com/jour/article/view/910аtrial fibrillationcardioversionamiodaronepropafenonepharmacoeconomic efficiency
collection DOAJ
language English
format Article
sources DOAJ
author T. A. Istomina
E. V. Serdechnaya
L. A. Kulminskaya
B. A. Tatarskiy
E. V. Kazakevich
V. L. Lipskiy
S. I. Martyushov
spellingShingle T. A. Istomina
E. V. Serdechnaya
L. A. Kulminskaya
B. A. Tatarskiy
E. V. Kazakevich
V. L. Lipskiy
S. I. Martyushov
EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)
Racionalʹnaâ Farmakoterapiâ v Kardiologii
аtrial fibrillation
cardioversion
amiodarone
propafenone
pharmacoeconomic efficiency
author_facet T. A. Istomina
E. V. Serdechnaya
L. A. Kulminskaya
B. A. Tatarskiy
E. V. Kazakevich
V. L. Lipskiy
S. I. Martyushov
author_sort T. A. Istomina
title EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)
title_short EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)
title_full EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)
title_fullStr EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)
title_full_unstemmed EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)
title_sort efficacy and safety of sinus rhythm restoration with amiodarone and propafenone in outpatients, economic aspects (based on data of n.a. semashko northern medical clinical center)
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2016-01-01
description Aim. To study efficacy and safey of sinus rhythm restoration with amiodarone and propafenone in outpatients with recurrent atrial fibrillation (AF), and to estimate pharmacoeconomic efficiency of such cardioversion in comparison with hospital treatment.Material and methods. Patients (n=199; aged 59.2±1.36) with paroxysmal (73.9%) or persistent (26.1%) AF were included into the multicenter prospective study. Follow-up period was 13.14 months (min 1 month, max 36 months). Patients with arrhythmia relapse <48 h received outpatient cardioversion with amiodarone or propafenone orally. Daily outpatient examination, including ECG and blood pressure monitoring every 30-60 min, was carried out to evaluate efficacy of cardioversion and hemodynamics. Phone contact with patients was available. Patients with unstable hemodynamics received cardioversion in hospital. Patients received propafenone in cumulative dose of 600 mg (150-300 mg every hour), and amiodarone 600-800 mg daily. The cost/effectiveness ratio (CER) was estimated. This ratio shows the cost of one unit of effect.Results. Outpatient cardioversion with amiodarone was started 24 h earlier (p=0.029) and with propafenone — 4.5 h earlier (p=0.002) than that in hospital. The average dose of amiodarone in ambulatory cardioversion was 1.3 times less (713.7±84,62 mg, p=0.345) than that in hospital cardioversion. Outpatient treatment with amiodarone restored sinus rhythm 8.7 h earlier, and with propafenone - 3.5 h earlier than the same treatments in hospital. Efficiency of hospital cardioversion with amiodarone was 70%, with propafenone - 80%, and efficiency of outpatient cardioversion — 96,1% and 98,4%, respectively. Outpatient treatment did not cause any severe side effects. Expenses for outpatient cardioversion made up 143 724.25 rubles, and for hospital cardioversion — 92 870.47 rubles. Average treatment costs for one patient in hospital was 6 times greater than for an outpatient. Outpatient cardioversion had the lowest CER (~1300 rubles%).Conclusion. Outpatient cardioversion with amiodarone or propafenone is not only effective and safe, but also economically feasible.
topic аtrial fibrillation
cardioversion
amiodarone
propafenone
pharmacoeconomic efficiency
url https://www.rpcardio.com/jour/article/view/910
work_keys_str_mv AT taistomina efficacyandsafetyofsinusrhythmrestorationwithamiodaroneandpropafenoneinoutpatientseconomicaspectsbasedondataofnasemashkonorthernmedicalclinicalcenter
AT evserdechnaya efficacyandsafetyofsinusrhythmrestorationwithamiodaroneandpropafenoneinoutpatientseconomicaspectsbasedondataofnasemashkonorthernmedicalclinicalcenter
AT lakulminskaya efficacyandsafetyofsinusrhythmrestorationwithamiodaroneandpropafenoneinoutpatientseconomicaspectsbasedondataofnasemashkonorthernmedicalclinicalcenter
AT batatarskiy efficacyandsafetyofsinusrhythmrestorationwithamiodaroneandpropafenoneinoutpatientseconomicaspectsbasedondataofnasemashkonorthernmedicalclinicalcenter
AT evkazakevich efficacyandsafetyofsinusrhythmrestorationwithamiodaroneandpropafenoneinoutpatientseconomicaspectsbasedondataofnasemashkonorthernmedicalclinicalcenter
AT vllipskiy efficacyandsafetyofsinusrhythmrestorationwithamiodaroneandpropafenoneinoutpatientseconomicaspectsbasedondataofnasemashkonorthernmedicalclinicalcenter
AT simartyushov efficacyandsafetyofsinusrhythmrestorationwithamiodaroneandpropafenoneinoutpatientseconomicaspectsbasedondataofnasemashkonorthernmedicalclinicalcenter
_version_ 1717816814268841984